A promising method has been developed to assess how changes in the immune response can help predict the effectiveness of a new immunotherapy in people with glioblastoma (GBM), the most common and deadly type of brain cancer.
A promising method has been developed to assess how changes in the immune response can help predict the effectiveness of a new immunotherapy in people with glioblastoma (GBM), the most common and deadly type of brain cancer.